PG
ALXN

PEAK6 Group’s Alexion Pharmaceuticals ALXN Stock Holding History

PEAK6 Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		$19.1M Buy
153,800
+61,500
+67% +$7.19M 0.08% 232
2018
Q1 		$10.3M Sell
92,300
-1,900
-2% -$227K 0.04% 434
2017
Q4 		$11.3M Buy
94,200
+1,600
+2% +$195K 0.05% 423
2017
Q3 		$13M Buy
92,600
+8,700
+10% +$1.18M 0.07% 304
2017
Q2 		$10.2M Buy
83,900
+13,900
+20% +$1.62M 0.06% 365
2017
Q1 		$8.49M Sell
70,000
-15,700
-18% -$2.02M 0.07% 342
2016
Q4 		$10.5M Buy
85,700
+36,700
+75% +$4.49M 0.07% 345
2016
Q3 		$6M Sell
49,000
-18,100
-27% -$2.33M 0.04% 590
2016
Q2 		$7.83M Buy
67,100
+43,000
+178% +$6.1M 0.06% 445
2016
Q1 		$3.35M Sell
24,100
-44,800
-65% -$6.58M 0.03% 846
2015
Q4 		$13.1M Sell
68,900
-25,600
-27% -$4.47M 0.09% 275
2015
Q3 		$14.8M Buy
94,500
+29,700
+46% +$5.42M 0.08% 312
2015
Q2 		$11.7M Buy
64,800
+1,300
+2% +$224K 0.07% 357
2015
Q1 		$11M Sell
63,500
-21,200
-25% -$3.84M 0.08% 286
2014
Q4 		$15.7M Buy
84,700
+17,100
+25% +$3.17M 0.12% 186
2014
Q3 		$11.2M Buy
67,600
+36,300
+116% +$5.96M 0.09% 275
2014
Q2 		$4.89M Sell
31,300
-51,900
-62% -$8.19M 0.05% 535
2014
Q1 		$12.7M Buy
83,200
+44,100
+113% +$7.01M 0.11% 197
2013
Q4 		$5.2M Sell
39,100
-39,100
-50% -$4.69M 0.04% 694
2013
Q3 		$4.55M Buy
78,200
+77,100
+7,009% +$8.46M 0.03% 838
2013
Q2 		$101 Buy
+1,100
New +$106K ﹤0.01% 4105

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

PEAK6 Group's ALXN Position: Q2 2018 in Review

PEAK6 Group increased its Alexion Pharmaceuticals (ALXN) stake by 42% in Q2 2018, buying an estimated $753K and bringing the position to 21,645 shares worth $2.69M. The position accounts for 0.01% of the portfolio, ranked #1144.

PEAK6 Group first reported a position in ALXN in Q2 2013 and has held it in 17 quarters since. The position peaked at $9.11M in Q2 2017. 600 funds tracked by Wall St. Rank hold ALXN as of Q2 2018.

  • PEAK6 Group held 21,645 shares of Alexion Pharmaceuticals worth $2.69M as of Q2 2018.
  • PEAK6 Group bought 6,446 Alexion Pharmaceuticals shares in Q2 2018, an estimated $753K.
  • Alexion Pharmaceuticals made up 0.01% of PEAK6 Group's portfolio in Q2 2018, its #1144 holding.
  • PEAK6 Group first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 17 quarters since.
  • PEAK6 Group's Alexion Pharmaceuticals position peaked at $9.11M in Q2 2017.
  • 600 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2018.

Based on PEAK6 Group's 13F filing for Q2 2018, filed 15 Aug 2018.